News Snapshot:
Ablaze Pharmaceuticals, a clinical-stage pharmaceutical company with offices in Shanghai and San Diego, has garnered $75 million in its Series A round funding, the firm announced on Monday. The fresh round was jointly led by AdvanTech Capital and Vivo Capital, a Palo Alto-based investment firm that backs the US and China healthcare market. It also attracted a portfolio of investors – including Hong Kong’s consortium Nan Fung Group’s Nan Fung Life Sciences and Pivotal Bioventure Partners China, as well as venBio Partners, Samsara BioCapital and Venrock Healthcare Capital Partners. Ablaze will invest the proceeds to set up a pipeline of...
